# US 2014/0193439 A1 · Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0193439 A1
- Document ID: US20140193439A1
- Status: Published application
- Kind: A1
- Application number: 14/148,359
- Filed: 2014-01-06
- Published: 2014-07-10
- Earliest claimed: 2009-09-14
- Assignees: The Trustees of the University of Pennsylvania
- Inventors: DAVID B. WEINER; KIMBERLY A. KRAYNYAK; MICHELE KUTZLER
- Web page: https://patentgrep.com/patent/US20140193439A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/7155: {for interleukins [IL]}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55527: {Interleukins}
- C12N 2740/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Compositions, recombinant vaccines and live alternated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-15Ra or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.

## Claims

### Claim 1

A composition comprising: an isolated nucleic acid molecule that encodes an immunogen; and an isolated nucleic acid molecule that encodes IL-15Rα or functional fragments thereof.

### Claim 2 (depends on 1)

The composition of claim 1 wherein said immunogen is a pathogen antigen, a cancer associated antigen or an antigen associated with cells involved in autoimmune diseases.

### Claim 3 (depends on 2)

The composition of claim 2 wherein said immunogen is a pathogen antigen from a pathogen that causes chronic infection.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said isolated nucleic acid molecule that encodes IL-15Ra comprises a nucleic acid coding sequence that encodes IL-15Ra having a sequence as set forth in SEQ ID NO:1.

### Claim 5 (depends on 1)

The composition of claim 1, further comprising a nucleic acid sequence that encodes IL-15 or a functional fragment thereof.

### Claim 6 (depends on 1)

The composition of claim 1, wherein said nucleic acid molecules are plasmids

### Claim 7 (depends on 1)

An injectable pharmaceutical composition comprising the composition of claim 1.

### Claim 8 (depends on 1)

A method of inducing an immune response in an individual against an immunogen comprising administering to said individual a composition according to claim 1.

### Claim 9

A recombinant vaccine comprising a nucleotide sequence that encodes an immunogen operably linked to regulatory elements, and a nucleotide sequence that encodes IL-15Rα or a functional fragment thereof.

### Claim 10 (depends on 9)

The recombinant vaccine of claim 9 wherein said immunogen is a pathogen antigen, a cancer-associated antigen or an antigen associated with cells involved in autoimmune diseases.

### Claim 11 (depends on 10)

The recombinant vaccine of claim 10 wherein said immunogen is a pathogen antigen from a pathogen that causes chronic infection.

### Claim 12 (depends on 9)

The recombinant vaccine of claim 9, wherein said isolated nucleic acid molecule that encodes IL-15Rα comprises anucleic acid coding sequence that encodes IL-15Ra having a sequence as set forth in SEQ ID NO:1.

### Claim 13 (depends on 9)

The recombinant vaccine of claim 9, further comprising a nucleic acid sequence that encodes IL-15 or a functional fragment thereof.

### Claim 14 (depends on 9)

A method of inducing an immune response in an individual against an immunogen comprising administering to said individual a recombinant vaccine of claim 9.

### Claim 15

A live attenuated pathogen comprising a nucleotide sequence that encodes IL-15Rα or a functional fragment thereof.

### Claim 16 (depends on 15)

The live attenuated pathogen of claim 15 wherein said pathogen is an attenuated strain of a pathogen that causes chronic infection.

### Claim 17 (depends on 15)

The live attenuated pathogen of claim 15 wherein the nucleic acid coding sequence that encodes IL-15Rα is SEQ ID NO:1.

### Claim 18 (depends on 15)

The live attenuated pathogen of claim 15 further comprising a nucleic acid sequence that encodes IL-15 or a functional fragment thereof.

### Claim 19 (depends on 15)

A method of inducing an immune response in an individual against an immunogen comprising administering to said individual a live attenuated pathogen of claim 15.

### Claim 20

A nucleic acid molecule comprising SEQ ID NO: 1 or a fragment thereof that has IL-15Rα immunomodulatory function, IL-15 binding function, binding function to other subunits of a IL-15 receptor complex, or a combination thereof.